Analysis of the susceptibility of CD57 T cells to CD3-mediated apoptosis.
After stimulation with anti-CD3 antibody in vitro, CD57(+) T cells showed a greater susceptibility to apoptosis than CD57(-)alphabetaT cell receptor (TCR)(+) T cells (regular alphabeta T cells). The apoptotic fraction of CD57(+) T cells showed an increased production of active caspase-3. An increase in both Fas expression and Fas-ligand (FasL) production was also observed in CD57(+) T cells, whereas the expression of survivin was suppressed in CD57(+) T cells compared to that of regular alphabeta T cells. CD57(+) T cells display a biased expansion of a few Vbeta T cell fractions in individuals, but such Vbeta T cells were not specifically susceptible to CD3-mediated apoptosis. The TCR expression level of CD57(+) T cells was much lower than that of regular T cells and anti-TCR antibody stimulation induced a smaller apoptotic proportion of CD57(+) T cells than did anti-CD3 antibody. Although the CD3epsilon expression levels were similar in both T cell subsets, the CD3zeta level of CD57(+) T cells was significantly higher than that of regular T cells. These results suggest that several apoptotic and anti-apoptotic molecules are involved in the CD3-induced apoptosis of CD57(+) T cells and raise the possibility that the imbalance in expression of the CD3epsilon and CD3zeta chains may also contribute to the susceptibility of CD57(+) T cells to undergo apoptosis.
Shinomiya
N
N
Department of Microbiology, National Defense Medical College, Tokorozawa, Japan.
Koike
Y
Y
Koyama
H
H
Takayama
E
E
Habu
Y
Y
Fukasawa
M
M
Tanuma
S
S
Seki
S
S
D000328:Adult; D000906:Antibodies / Q000494:pharmacology; D017209:Apoptosis / Q000276:immunology; D017252:CD3 Complex / Q000737:chemistry / Q000276:immunology*; D018959:CD57 Antigens / Q000276:immunology*; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D002478:Cells, Cultured; D053222:Fas Ligand Protein; D006801:Humans; D007139:Immunoglobulin epsilon-Chains / Q000032:analysis; D007142:Immunoglobulin gamma-Chains / Q000032:analysis; D051034:Inhibitor of Apoptosis Proteins; D008562:Membrane Glycoproteins / Q000032:analysis / Q000276:immunology; D008869:Microtubule-Associated Proteins / Q000032:analysis / Q000276:immunology; D009363:Neoplasm Proteins; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077022:Survivin; D013601:T-Lymphocytes / Q000276:immunology*; D019014:fas Receptor / Q000032:analysis / Q000276:immunology
D000906:Antibodies; C107489:BIRC5 protein, human; D017252:CD3 Complex; D018959:CD57 Antigens; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007139:Immunoglobulin epsilon-Chains; D007142:Immunoglobulin gamma-Chains; D051034:Inhibitor of Apoptosis Proteins; D008562:Membrane Glycoproteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D016693:Receptors, Antigen, T-Cell, alpha-beta; D000077022:Survivin; D019014:fas Receptor; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases